Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials

Phase 1

  • TBAJ-876
    • TBAJ-876
  • TBI-223
    • TBI-223 / Oxazolidinone
    Institute of Materia Medica
  • PK of First-Line Drugs in Children <5kg
    • Isoniazid / Rifampin / Pyrazinamide / Ethambutol Pediatric HRZE

Phase 2

  • Sutezolid
    • Sutezolid / Oxazolidinone
    Bill & Melinda Gates Medical Research Institute
  • TBA-7371
    • TBA-7371 / DprE1 Inhibitor
    Foundation for Neglected Disease Research, Bill & Melinda Gates Medical Research Institute

Phase 3

  • SimpliciTB
    • Bedaquiline / Pretomanid / Moxifloxacin / Pyrazinamide BPaMZ
    PanACEA, Mylan
  • ZeNix
    • Bedaquiline / Pretomanid / Linezolid BPaL
    Mylan
  • Nix-TB
    • Bedaquiline / Pretomanid / Linezolid BPaL
    Mylan

Phase 4

  • Optimized First-Line Drugs in Children >5kg
    • Ethambutol
    • Pyrazinamide
    • Isoniazid
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

New Report Highlights Urgent Need for Improved Treatments for Children with MDR-TB
Standing Against Racism and Injustice
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2020 The TB Alliance. All Rights Reserved. Site by Darby Communications